- Article
- Source: Campus Sanofi
- 23 Oct 2023
Specific characteristics of Praluent® (alirocumab)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/dyslipidaemia/specific-characteristics/Hero/bcg_characteristic.jpg/jcr:content/bcg_characteristic.jpg)
![Praluent logo](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Praluent_hero.png/jcr:content/Praluent_hero.png)
Pharmacological properties
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Dyslipidaemia/specific-characteristics/Image/Desktop_Specific_Characteristics_Pharmacological_Diagram.jpg/jcr:content/Desktop_Specific_Characteristics_Pharmacological_Diagram.jpg)
Figure © Sanofi.
Praluent®
Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Dyslipidaemia/unmet-needs/Image/Group-44.jpg/jcr:content/Group%2044.jpg)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/admelog/MicrosoftTeams-image--2-.png6/jcr:content/MicrosoftTeams-image%20(2).png)
References
- Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed October 2023.
- Kuhnast S, et al. J Lipid Res 2014;55:2103–2112.
MAT-XU-2204595 (v3.0) Date of Preparation: October 2023